Tuberculosis screening

Jump to navigation Jump to search

Tuberculosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tuberculosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Children

HIV Coinfection

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Special Conditions
Drug-resistant

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tuberculosis screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tuberculosis screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tuberculosis screening

CDC on Tuberculosis screening

Tuberculosis screening in the news

Blogs on Tuberculosis screening

Directions to Hospitals Treating Tuberculosis

Risk calculators and risk factors for Tuberculosis screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Screening for tuberculosis is generally done with using a mantoux tuberculin skin test, also known as a tuberculin skin test or a PPD. The test involves injecting a small amount of a purified protein derivative of the tuberculosis bacterium intradermally, and watching for a reaction in the following days.

Screening

The results of a Mantoux tuberculin skin test must be interpreted carefully. The person's medical risk factors determine at which increment (5 mm, 10 mm, or 15 mm) of induration the result is considered positive.[1] A positive result indicates TB exposure.

  • 10 mm or more is positive in
    • Recent arrivals (less than 5 years) from high-prevalence countries
    • Injection drug users
    • Residents and employees of high-risk congregate settings (e.g., prisons, nursing homes, hospitals, homeless shelters, etc.)
    • Mycobacteriology lab personnel
    • Persons with clinical conditions that place them at high risk (e.g., diabetes, prolonged corticosteroid therapy, leukemia, end-stage renal disease, chronic malabsorption syndromes, low body weight, etc)
    • Children less than 4 years of age, or children and adolescents exposed to adults in high-risk categories
  • 15 mm or more is positive in
    • Persons with no known risk factors for TB
    • (Note: Targeted skin testing programs should only be conducted among high-risk groups)

A few important notes about Mantoux tuberculin skin tests:

  • A tuberculin test conversion is defined as an increase of 10 mm or more within a 2-year period, regardless of age.
  • Mycobacterium avium intracellulare (MAI) or other mycobacterium cause 5 mm induration, but TB is what causes ≥10mm.
  • Decision to test is decision to treat.
  • If a patient is treated fully, then re-exposed, they should only be retreated if they are HIV positive (immunocompromised) or the risk of reinfection is high.

Contact Screening

When someone is diagnosed with tuberculosis, all their close contacts should be screened for TB with a tuberculin skin test or a chest x-ray or both.

References

  1. From the CDC team of the CDC team at the Saskatchewan Lung Association, photos of a PPD bump.

Template:WH Template:WS